DMIIU
Drugs Made In America Acquisition II Corp.
Price Chart
Latest Quote
$10.12
+0.00 (+0.00%)
Current Price
| Previous Close | $10.12 |
| Open | $10.11 |
| Day High | $10.12 |
| Day Low | $10.12 |
| Volume | 151 |
Stock Information
| Total Debt | $450K |
| Cash Equivalents | $348K |
| Net Income | $8.58M |
| Sector | Financial Services |
| Industry | Shell Companies |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $644.75M |
| Income | $8.58M |
| Book/sh | $-0.28 |
Financial Ratios
| Quick Ratio | 0.52 |
| Current Ratio | 0.53 |
Returns & Margins
Ownership
| Insider Ownership | 1.07% |
| Institutional Ownership | 6.84% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | -36.14 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $10.14 |
| SMA50 | $10.10 |
| RSI | 41.46 |
| ATR | 0.0146 |
| Shares Float | 50.26M |
| Short Ratio | 0.05 |
Performance History
| Week | +0.00% |
| Month | -0.30% |
| Quarter | +1.00% |
| 6 Months | +1.10% |
| YTD | +1.20% |
| 10 Years | +1.30% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $10.12 | 0 |
| 2026-06-17 | $10.12 | 0 |
| 2026-06-16 | $10.12 | 0 |
| 2026-06-15 | $10.12 | 0 |
| 2026-06-12 | $10.12 | 0 |
| 2026-06-11 | $10.12 | 3,600 |
| 2026-06-10 | $10.11 | 0 |
| 2026-06-09 | $10.11 | 3,700 |
| 2026-06-08 | $10.23 | 7,000 |
| 2026-06-05 | $10.15 | 0 |
| 2026-06-04 | $10.15 | 400 |
| 2026-06-03 | $10.15 | 0 |
| 2026-06-02 | $10.15 | 0 |
| 2026-06-01 | $10.15 | 0 |
| 2026-05-29 | $10.15 | 300 |
| 2026-05-28 | $10.11 | 0 |
| 2026-05-27 | $10.11 | 0 |
| 2026-05-26 | $10.11 | 6,000 |
| 2026-05-22 | $10.15 | 0 |
| 2026-05-21 | $10.15 | 0 |
| 2026-05-20 | $10.15 | 1,500 |
| 2026-05-19 | $10.15 | 500 |
About Drugs Made In America Acquisition II Corp.
Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp. was incorporated in 2024 and is based in New York, New York.
đ° Latest News
NexGen Energyâs Rook I Project Emerges as a Key Source in the Next Uranium Supply Wave
Motley Fool âĸ 2026-02-24T21:42:00Z
Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) is largely controlled by institutional shareholders who own 79% of the company
Simply Wall St. âĸ 2025-12-04T15:05:53Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 |
|---|---|
| Revenue | |
| Total Revenue | $0 |
| Operating Revenue | $0 |
| Expenses | |
| Total Expenses | $1,300,498 |
| Other Income Expense | $553,748 |
| Net Non Operating Interest Income Expense | $4,933,800 |
| Operating Expense | $1,300,498 |
| General And Administrative Expense | $488,385 |
| Income & Earnings | |
| Net Income From Continuing Operation Net Minority Interest | $4,187,050 |
| Net Interest Income | $4,933,800 |
| Interest Income | $4,933,800 |
| Normalized Income | $3,749,589 |
| Net Income From Continuing And Discontinued Operation | $4,187,050 |
| Total Operating Income As Reported | $-488,385 |
| Net Income Common Stockholders | $4,187,050 |
| Net Income | $4,187,050 |
| Net Income Including Noncontrolling Interests | $4,187,050 |
| Net Income Continuous Operations | $4,187,050 |
| Pretax Income | $4,187,050 |
| Special Income Charges | $553,748 |
| Interest Income Non Operating | $4,933,800 |
| Operating Income | $-1,300,498 |
| Other | |
| Tax Effect Of Unusual Items | $116,287 |
| Tax Rate For Calcs | $0 |
| Normalized EBITDA (Bullshit earnings) | $-1,854,246 |
| Total Unusual Items | $553,748 |
| Total Unusual Items Excluding Goodwill | $553,748 |
| EBITDA (Bullshit earnings) | $-1,300,498 |
| EBIT | $-1,300,498 |
| Diluted NI Availto Com Stockholders | $4,187,050 |
| Other Special Charges | $-553,748 |
| Provision For Doubtful Accounts | $812,113 |
| Selling General And Administration | $488,385 |
| Other Gand A | $488,385 |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $487,158,973 | $-116,719 |
| Total Assets | $504,959,837 | $138,064 |
| Total Non Current Assets | $504,933,800 | $78,449 |
| Other Non Current Assets | $504,933,800 | - |
| Non Current Deferred Assets | $0 | $78,449 |
| Current Assets | $26,037 | $59,615 |
| Prepaid Assets | $25,814 | $42,580 |
| Receivables | $0 | $0 |
| Cash Cash Equivalents And Short Term Investments | $223 | $17,035 |
| Cash And Cash Equivalents | $223 | $17,035 |
| Cash Financial | $223 | $17,035 |
| Debt | ||
| Net Debt | - | $233,065 |
| Total Debt | - | $250,100 |
| Current Debt And Capital Lease Obligation | - | $250,100 |
| Current Debt | - | $250,100 |
| Other Current Borrowings | - | $250,100 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $17,800,864 | $254,783 |
| Total Non Current Liabilities Net Minority Interest | $17,500,000 | $0 |
| Tradeand Other Payables Non Current | $17,500,000 | $0 |
| Current Liabilities | $300,864 | $254,783 |
| Payables And Accrued Expenses | $300,864 | $4,683 |
| Payables | $99,359 | - |
| Accounts Payable | $99,359 | $0 |
| Equity | ||
| Common Stock Equity | $487,158,973 | $-116,719 |
| Total Equity Gross Minority Interest | $487,158,973 | $-116,719 |
| Stockholders Equity | $487,158,973 | $-116,719 |
| Retained Earnings | $-17,776,196 | $-151,719 |
| Other | ||
| Ordinary Shares Number | $63,700,000 | $63,700,000 |
| Share Issued | $63,700,000 | $63,700,000 |
| Tangible Book Value | $487,158,973 | $-116,719 |
| Invested Capital | $487,158,973 | $133,381 |
| Working Capital | $-274,827 | $-195,168 |
| Total Capitalization | $487,158,973 | $-116,719 |
| Additional Paid In Capital | $0 | $33,563 |
| Capital Stock | $504,935,169 | $1,437 |
| Common Stock | $504,935,169 | $1,437 |
| Preferred Stock | $0 | $0 |
| Current Accrued Expenses | $201,505 | $4,683 |
| Duefrom Related Parties Current | $0 | $0 |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 |
|---|---|
| Free Cash Flow | |
| Free Cash Flow | $-1,018,231 |
| Operating Activities | |
| Operating Cash Flow | $-1,018,231 |
| Cash Flow From Continuing Operating Activities | $-1,018,231 |
| Operating Gains Losses | $-553,748 |
| Investing Activities | |
| Investing Cash Flow | $-500,000,000 |
| Cash Flow From Continuing Investing Activities | $-500,000,000 |
| Financing Activities | |
| Issuance Of Capital Stock | $502,000,000 |
| Financing Cash Flow | $501,001,419 |
| Cash Flow From Continuing Financing Activities | $501,001,419 |
| Net Other Financing Charges | $-464,800 |
| Net Common Stock Issuance | $502,000,000 |
| Common Stock Issuance | $502,000,000 |
| Other | |
| Repayment Of Debt | $-533,781 |
| Issuance Of Debt | $0 |
| End Cash Position | $223 |
| Beginning Cash Position | $17,035 |
| Changes In Cash | $-16,812 |
| Net Issuance Payments Of Debt | $-533,781 |
| Net Short Term Debt Issuance | $-533,781 |
| Short Term Debt Payments | $-533,781 |
| Short Term Debt Issuance | $0 |
| Net Investment Purchase And Sale | $-500,000,000 |
| Purchase Of Investment | $-500,000,000 |
| Change In Working Capital | $-607,645 |
| Change In Payables And Accrued Expense | $187,702 |
| Change In Accrued Expense | $88,343 |
| Change In Payable | $99,359 |
| Change In Account Payable | $99,359 |
| Change In Prepaid Assets | $16,766 |
| Change In Receivables | $-812,113 |
| Other Non Cash Items | $-4,856,001 |
| Provisionand Write Offof Assets | $812,113 |
| Net Income From Continuing Operations | $4,187,050 |
Fetched: 2026-06-19